Clinical Trial Update: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for lebikizumab in participants with persistent moderate to severe atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED